Basilea Pharmaceutica AG (SWX:BSLN)

Basilea Pharmaceutica AG Balance Sheet

Financials in millions CHF. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	173.05	159.8	120.71	59.93	84.66	53.7
Short-Term Investments	-	-	-	-	-	95
Cash & Short-Term Investments	173.05	159.8	120.71	59.93	84.66	148.7
Cash Growth	34.81%	32.38%	101.41%	-29.21%	-43.07%	-8.08%
Accounts Receivable	13.88	13.49	8.88	27.89	33.15	24.95
Other Receivables	54.29	49.79	49.31	30.26	28.55	39.5
Receivables	68.17	63.28	58.18	58.15	61.7	64.45
Inventory	26.04	21.56	31.61	26.41	24.24	22.78
Restricted Cash	2.93	2.54	3.85	4.39	1.91	1.25
Other Current Assets	3.62	4.56	6.56	3.27	2.85	3.88
Total Current Assets	273.81	251.73	220.91	152.15	175.36	241.07
Property, Plant & Equipment	16.79	18.15	18.98	20.55	21.57	2.92
Other Intangible Assets	0.23	0.37	0.37	0.55	0.58	0.63
Long-Term Deferred Tax Assets	7.17	11.7	17.33	-	-	-
Other Long-Term Assets	0.04	0.05	0.17	0.04	22.07	0.26
Total Assets	298.04	282	257.76	173.29	220.85	247.27

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	13.98	15.06	11.49	5.85	0.19	10.62
Accrued Expenses	22.8	23.9	21.5	13.1	18.9	27.9
Current Portion of Long-Term Debt	-	-	-	15.45	37.47	123.51
Current Portion of Leases	2.06	2.06	2.06	2.06	1.99	0.9
Current Income Taxes Payable	-	-	-	-	-	0.5
Current Unearned Revenue	1.58	1.57	1.62	1.23	1.23	1.23
Other Current Liabilities	1.1	6.62	8.89	9.9	15.07	9.76
Total Current Liabilities	41.51	49.22	45.56	47.59	74.85	174.41
Long-Term Debt	70.64	75.44	95.91	95.46	131.36	94.54
Long-Term Leases	10.74	11.72	13.7	15.64	16.32	0.01
Long-Term Unearned Revenue	8.72	9.46	11.39	9.46	10.69	11.93
Pension & Post-Retirement Benefits	4.07	8.23	10.21	15.15	8.34	24.99
Other Long-Term Liabilities	-	-	-	0	-0	-
Total Liabilities	135.68	154.06	176.77	183.29	241.56	305.87

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	13.43	13.32	13.17	13.1	13.09	12.99
Additional Paid-In Capital	1,055	1,052	1,048	1,042	1,037	1,030
Retained Earnings	-854.62	-882.57	-923.29	-1,001	-1,011	-1,023
Treasury Stock	-50.99	-51.28	-51.7	-54.01	-56.07	-56.56
Comprehensive Income & Other	-0.56	-3.9	-4.74	-10.21	-3.79	-21.62
Shareholders' Equity	162.35	127.94	81	-10	-20.72	-58.61
Total Liabilities & Equity	298.04	282	257.76	173.29	220.85	247.27

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	83.44	89.22	111.67	128.61	187.14	218.96
Net Cash (Debt)	89.61	70.58	9.04	-68.67	-102.48	-70.26
Net Cash Growth	183.76%	680.74%	-	-	-	-
Net Cash Per Share	6.56	5.16	0.65	-5.66	-8.58	-6.01
Filing Date Shares Outstanding	12.4	12.29	12.13	12	11.95	11.84
Total Common Shares Outstanding	12.4	12.29	12.13	12	11.95	11.84
Working Capital	232.29	202.52	175.35	104.55	100.51	66.66
Book Value Per Share	13.09	10.41	6.68	-0.83	-1.73	-4.95
Tangible Book Value	162.12	127.57	80.63	-10.55	-21.29	-59.24
Tangible Book Value Per Share	13.07	10.38	6.65	-0.88	-1.78	-5.00
Machinery	15.15	14.85	13.61	12.86	12.98	16.62
Leasehold Improvements	2	2	1.8	1.8	1.8	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 22, 2026

Data Sources Report a data error